



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider genetic testing for Rett syndrome (RTT)–associated genes (e.g., methyl-CpG-binding protein 2 [*MECP2*], forkhead box G1 [*FOXG1*], or cyclin-dependent kinase-like 5 [*CDKL5*]) to establish a genetic diagnosis of Rett syndrome (RTT) in a child with developmental delay and signs/symptoms of Rett syndrome (RTT), when a definitive diagnosis cannot be made without genetic testing to be **eligible for coverage**.**

Based on review of available data, the Company may consider targeted genetic testing for a known familial Rett syndrome (RTT)–associated variant to determine carrier status of a first-degree female relatives (a mother or a sister) of an individual with Rett syndrome (RTT) to be **eligible for coverage**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers all other indications for genetic testing for Rett syndrome (RTT)–associated genes (e.g., methyl-CpG-binding protein 2 [*MECP2*], forkhead box G1 [*FOXG1*], or cyclin-dependent kinase-like 5 [*CDKL5*]), including routine carrier testing (preconception or prenatal) in persons with negative family history, and testing of asymptomatic family members to determine future risk of disease, to be **investigational**.*

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

When Services Are Not Covered

Based on review of available data, the Company considers repeat germline testing to be **not covered****.

Note:

Repeat germline testing that investigates the same genetic information is not reasonable and necessary as it is duplicative and not required for medical treatment decisions. Examples of germline tests include, but are not limited to, single gene testing, gene panel tests, and whole exome or whole genome sequencing for inherited disorders and pharmacogenomic/cytochrome P450 testing.

Policy Guidelines

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology-"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"-to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives
--	------------------	---

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Background/Overview

Rett Syndrome

Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily affecting girls, with an incidence of 1 in 10,000 female births and a prevalence of 7.1 per 100,000 females, making it among the most common genetic causes of intellectual disability in girls. In its typical form, RTT is characterized by apparently normal development for the first 6 to 18 months of life, followed by

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

regression of intellectual functioning, acquired fine and gross motor skills, and social skills. Purposeful use of the hands is replaced by repetitive stereotyped hand movements, such as hand-wringing. Other clinical manifestations include seizures, disturbed breathing patterns with hyperventilation and periodic apnea, scoliosis, growth retardation, and gait apraxia.

There is wide variability in the rate of progression and severity of the disease. In addition to the typical (or classic) form of RTT, there are recognized atypical variants. Three distinct atypical variants have been described: preserved speech, early seizure, and congenital variants. RTT occurring in males is also considered a variant type and is associated with somatic mosaicism or Klinefelter (XXY) syndrome. A small number of RTT cases in males arising from the *MECP2* exon 1 variant have been reported. Diagnostic criteria for typical (or classic) RTT and atypical (or variant) RTT have been established. For typical RTT, a period of regression followed by recovery or stabilization and fulfillment of all the main criteria are required to meet the diagnostic criteria for classic RTT. For atypical RTT, a period of regression followed by recovery or stabilization, at least 2 of the 4 main criteria, plus 5 of 11 supportive are required to meet the diagnostic criteria of variant RTT.

Treatment

Currently, there are no specific treatments that halt or reverse disease progression, and there are no known medical interventions that will change the outcome of patients with RTT. Management is mainly symptomatic and individualized, focusing on optimizing each individual's abilities. A multidisciplinary approach is usually applied, with specialist input from dietitians, physical therapists, occupational therapists, speech therapists, and music therapists. Regular monitoring for scoliosis (seen in »87% of patients by age 25 years) and possible heart abnormalities, particularly cardiac conduction abnormalities, may be recommended. Spasticity can have a major impact on mobility; physical therapy and hydrotherapy may prolong mobility. Occupational therapy can help children develop communication strategies and skills needed for performing self-directed activities (e.g., dressing, feeding, practicing arts and crafts).

Pharmacologic approaches to managing problems associated with RTT include melatonin for sleep disturbances and several agents to control breathing disturbances, seizures, and stereotypic movements. RTT patients have an increased risk of life-threatening arrhythmias associated with a prolonged QT interval, and avoidance of a number of drugs is recommended, including prokinetic

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

agents, antipsychotics, tricyclic antidepressants, antiarrhythmics, anesthetic agents, and certain antibiotics.

In a mouse model of RTT, genetic manipulation of the *MECP2* gene has demonstrated reversibility of the genetic defect.

Genetics

RTT is an X-linked dominant genetic disorder. Pathogenic variants in the *MECP2* gene, which is thought to control expression of several genes, including some involved in brain development, were first reported in 1999. Subsequent screening has shown that over 80% of patients with classic RTT have pathogenic variants in the *MECP2* gene. More than 200 pathogenic variants in *MECP2* have been associated with RTT. However, 8 of the most commonly occurring missense and nonsense variants account for almost 70% of all cases; small C-terminal deletions account for approximately 10%; and large deletions, 8% to 10%. *MECP2* variant type is associated with disease severity. Whole duplications of the *MECP2* gene have been associated with a severe X-linked intellectual disability with progressive spasticity, no or poor speech acquisition, and acquired microcephaly. Additionally, the pattern of X-chromosome inactivation influences the severity of the clinical disease females.

Because the spectrum of clinical phenotypes is broad, to facilitate genotype-phenotype correlation analyses, the International Rett Syndrome Association has established a locus-specific *MECP2* variation database (RettBASE) and a phenotype database (InterRett).

Approximately 99.5% of cases of RTT are sporadic, resulting from a de novo variant, which arises almost exclusively on the paternally derived X chromosome. The remaining 0.5% of cases are familial and usually explained by germline mosaicism or favorably skewed X-chromosome inactivation in the carrier mother that results in her being unaffected or only slightly affected (mild intellectual disability). In the case of a carrier mother, the recurrence risk of RTT is 50%. If a variant is not identified in leukocytes of the mother, the risk to a sibling of the proband is below 0.5% (because germline mosaicism in either parent cannot be excluded).

Identification of a variant in *MECP2* does not necessarily equate to a diagnosis of RTT. Rare cases of *MECP2* variants also have been reported in other clinical phenotypes, including individuals with an Angelman-like picture, nonsyndromic X-linked intellectual disability, PPM-X syndrome (an X-linked genetic disorder characterized by psychotic disorders [most commonly bipolar disorder],

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

parkinsonism, and intellectual disability), autism, and neonatal encephalopathy. Recent studies have revealed that different classes of genetic variants in *MECP2* result in variable clinical phenotypes and overlap with other neurodevelopmental disorders.

A proportion of patients with a clinical diagnosis of RTT do not appear to have pathogenic variants in the *MECP2* gene. Two other genes (*CDKL5*, *FOXG1*) have been shown to be associated with atypical variants.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Genetic testing for Rett syndrome is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Description

Rett syndrome (RTT), a neurodevelopmental disorder, is usually caused by pathogenic variants in the methyl-CpG-binding protein 2 (*MECP2*) gene. Genetic testing is available to determine whether a pathogenic variant exists in RTT-associated genes (e.g., *MECP2*, *FOXG1*, or *CDLK5*) in an individual with clinical features of RTT or an individual's family member.

Summary of Evidence

For individuals who have signs and/or symptoms of Rett syndrome (RTT) who receive genetic testing for RTT-associated genes, the evidence includes case series and prospective cohort studies.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, health status measures, and quality of life. Methyl-CpG-binding protein 2 (*MECP2*) variants are found in most patients with RTT, particularly in those who present with classic clinical features of RTT. The diagnostic accuracy of genetic testing for RTT cannot be determined with absolute certainty given variable clinical presentations of typical versus atypical RTT, but testing appears to have high sensitivity and specificity. Genetic testing has clinical utility when signs and symptoms of RTT are present to establish a specific genetic diagnosis. Identification of a specific class or type of pathogenic variant may alter some aspects of management and may eliminate or necessitate surveillance for different clinical manifestations of the disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic sisters of an individual with RTT who receive targeted genetic testing for a known familial RTT-associated variant, the evidence includes case series and prospective cohort studies. Relevant outcomes are test accuracy and validity, other test performance measures, changes in reproductive decision making, symptoms, and symptoms. Targeted familial variant testing of asymptomatic sisters can eliminate or necessitate surveillance given the variability of clinical presentation in girls due to X-chromosome inactivation and clinical severity based on the type of pathogenic variant present. In sisters of reproductive age, determination of carrier status can eliminate or necessitate prenatal testing and inform reproductive decision making. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are females with a child with RTT who are considering future childbearing who receive targeted genetic testing for a known familial RTT-associated variant, the evidence includes cases series and prospective cohort studies. Relevant outcomes are test accuracy and validity, other test performance measures, and changes in reproductive decision making. Targeted familial variant testing of a woman with a child with RTT to determine carrier status may inform prenatal testing and reproductive decision making. In the rare situation where the mother carries a pathogenic variant, all future offspring have a 50% of being affected, with males typically presenting with more severe disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input on the use of variant testing for Rett syndrome (RTT) was received from 2 specialty medical societies (3 reviewers) and 3 academic medical centers, for a total of 6 reviewers, while this policy was under review in 2012. There was consensus or near consensus supporting the use of variant testing for the diagnosis of RTT in a girl in whom the clinical differential diagnosis includes RTT, especially when clinical diagnosis is uncertain. Support for testing sisters of individuals with RTT and prenatal screening was mixed.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Neurology and Child Neurology Society

In 2011, the American Academy of Neurology and the Child Neurology Society issued an evidence report on genetic and metabolic testing of children with global developmental delay. The 2 societies recommended considering methyl-CpG-binding protein 2 (*MECP2*) genetic testing for all girls with unexplained moderate-to-severe developmental delay.

American Academy of Pediatrics

In 2007, the American Academy of Pediatrics (AAP) issued a policy statement (reaffirmed in 2014 and 2019) recommending *MECP2* testing to confirm a diagnosis of suspected Rett syndrome (RTT), especially when the diagnosis was unclear from symptoms alone.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

In 2020, the AAP published Clinical Report Guidance on the identification, evaluation, and management of children with autism spectrum disorder which stated that "if patient is a girl, consider evaluation for Rett syndrome, MECP2 testing."

Neither the American Academy of Neurology nor the American Academy of Pediatrics has provided recommendations on when to use *CDKL5* or *FOXG1* testing.

American College of Medical Genetics and Genomics

In 2013, the American College of Medical Genetics and Genomics revised its evidence-based guidelines for clinical genetics evaluation of autism spectrum disorders. Testing for *MECP2* genetic variants was recommended as part of the diagnostic workup of females who present with an autistic phenotype. Routine *MECP2* testing in males with autism spectrum disorders was not recommended.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT02171104	MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG	100	Dec 2022

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Unpublished</i>			
NCT02153723	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	20	Jan 2016 (updated 11/05/2018)
NCT01777542	Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1 (Mecasermin [rDNA] Injection)	30	Nov 2016 (updated 03/26/2018)
NCT01520363	Placebo Controlled Trial of Dextromethorphan in Rett Syndrome	60	Oct 2016 (updated 12/04/2018)

NCT: national clinical trial.

References

1. Williamson SL, Christodoulou J. Rett syndrome: new clinical and molecular insights. *Eur J Hum Genet.* Aug 2006; 14(8): 896-903. PMID 16865103
2. Petriti U, Dudman DC, Scosyrev E, et al. Global prevalence of Rett syndrome: systematic review and meta-analysis. *Syst Rev.* Jan 16 2023; 12(1): 5. PMID 36642718
3. Lotan M, Ben-Zeev B. Rett syndrome. A review with emphasis on clinical characteristics and intervention. *ScientificWorldJournal.* Dec 06 2006; 6: 1517-41. PMID 17160339
4. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol.* Dec 2010; 68(6): 944-50. PMID 21154482
5. Guy J, Gan J, Selfridge J, et al. Reversal of neurological defects in a mouse model of Rett syndrome. *Science.* Feb 23 2007; 315(5815): 1143-7. PMID 17289941
6. Robinson L, Guy J, McKay L, et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. *Brain.* Sep 2012; 135(Pt 9): 2699-710. PMID 22525157
7. Suter B, Treadwell-Deering D, Zoghbi HY, et al. Brief report: MECP2 mutations in people without Rett syndrome. *J Autism Dev Disord.* Mar 2014; 44(3): 703-11. PMID 23921973

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

8. Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. *J Med Genet.* Mar 2014; 51(3): 152-8. PMID 24399845
9. Archer H, Evans J, Leonard H, et al. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. *J Med Genet.* Feb 2007; 44(2): 148-52. PMID 16905679
10. Weaving LS, Williamson SL, Bennetts B, et al. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. *Am J Med Genet A.* Apr 15 2003; 118A(2): 103-14. PMID 12655490
11. Liyanage VR, Rastegar M. Rett syndrome and MeCP2. *Neuromolecular Med.* Jun 2014; 16(2): 231-64. PMID 24615633
12. Zahorakova D, Lelkova P, Gregor V, et al. MECP2 mutations in Czech patients with Rett syndrome and Rett-like phenotypes: novel mutations, genotype-phenotype correlations and validation of high-resolution melting analysis for mutation scanning. *J Hum Genet.* Jul 2016; 61(7): 617-25. PMID 26984561
13. Sheikh TI, Ausió J, Faghfoury H, et al. From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2. *Sci Rep.* Dec 08 2016; 6: 38590. PMID 27929079
14. Schönewolf-Greulich B, Tejada MI, Stephens K, et al. The MECP2 variant c.925C T (p.Arg309Trp) causes intellectual disability in both males and females without classic features of Rett syndrome. *Clin Genet.* Jun 2016; 89(6): 733-8. PMID 26936630
15. Huppke P, Laccone F, Krämer N, et al. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. *Hum Mol Genet.* May 22 2000; 9(9): 1369-75. PMID 10814718
16. Cheadle JP, Gill H, Fleming N, et al. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. *Hum Mol Genet.* Apr 12 2000; 9(7): 1119-29. PMID 10767337
17. Bao X, Downs J, Wong K, et al. Using a large international sample to investigate epilepsy in Rett syndrome. *Dev Med Child Neurol.* Jun 2013; 55(6): 553-8. PMID 23421866
18. Bebbington A, Downs J, Percy A, et al. The phenotype associated with a large deletion on MECP2. *Eur J Hum Genet.* Sep 2012; 20(9): 921-7. PMID 22473088
19. Lane JB, Lee HS, Smith LW, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. *Neurology.* Nov 15 2011; 77(20): 1812-8. PMID 22013176

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

20. Fabio RA, Colombo B, Russo S, et al. Recent insights into genotype-phenotype relationships in patients with Rett syndrome using a fine grain scale. *Res Dev Disabil.* Nov 2014; 35(11): 2976-86. PMID 25124696
21. Halbach N, Smeets EE, Julu P, et al. Neurophysiology versus clinical genetics in Rett syndrome: A multicenter study. *Am J Med Genet A.* Sep 2016; 170(9): 2301-9. PMID 27354166
22. Pidcock FS, Salorio C, Bibat G, et al. Functional outcomes in Rett syndrome. *Brain Dev.* Jan 2016; 38(1): 76-81. PMID 26175308
23. Sajan SA, Jhangiani SN, Muzny DM, et al. Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2. *Genet Med.* Jan 2017; 19(1): 13-19. PMID 27171548
24. Vidal S, Brandi N, Pacheco P, et al. The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome. *Sci Rep.* Sep 25 2017; 7(1): 12288. PMID 28947817
25. Zhang Q, Zhao Y, Bao X, et al. Familial cases and male cases with MECP2 mutations. *Am J Med Genet B Neuropsychiatr Genet.* Jun 2017; 174(4): 451-457. PMID 28394482
26. Amir RE, Sutton VR, Van den Veyver IB. Newborn screening and prenatal diagnosis for Rett syndrome: implications for therapy. *J Child Neurol.* Sep 2005; 20(9): 779-83. PMID 16225835
27. Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology.* Oct 25 2011; 77(17): 1629-35. PMID 21956720
28. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. *Pediatrics.* Nov 2007; 120(5): 1183-215. PMID 17967920
29. AAP Publications Retired and Reaffirmed. *Pediatrics.* Dec 2014; 134(5): e1520.
30. Hyman SL, Levy SE, Myers SM, et al. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics.* Jan 2020; 145(1). PMID 31843864
31. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med.* May 2013; 15(5): 399-407. PMID 23519317

Policy History

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

11/07/2013 Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

11/20/2013	Medical Policy Implementation Committee approval. New policy.
12/04/2014	Medical Policy Committee review
12/17/2014	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
12/03/2015	Medical Policy Committee review
12/16/2015	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/01/2016	Medical Policy Committee review
12/21/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017	Medical Policy Committee review
12/20/2017	Medical Policy Implementation Committee approval. The policy is revised with updated genetics nomenclature. "Mutations" changed to "variants" in policy statements. Policy rewritten with new PICOs for indications 2 and 3 to limit populations to sisters of child with Rett syndrome (indication 2) or females with a child with Rett syndrome (indication 3) with the intervention revised to "targeted genetic testing for a known familial variant." Policy statements updated to define "genetic testing for Rett syndrome– associated genes (e.g., <i>MECP2</i> , <i>FOXG1</i> , or <i>CDKL5</i>)"; Removed "female" requirement of child for testing; Added 2 new medical necessity statements for "targeted genetic testing for a known familial variant" in a sister of a child with Rett syndrome or a female with a child with Rett syndrome.
12/06/2018	Medical Policy Committee review
12/19/2018	Medical Policy Implementation Committee approval. Edited the investigational statement as follows: added examples of associated genes for Rett syndrome; added "routine" to describe carrier testing; added "persons with negative family history" to routine carrier testing.
12/05/2019	Medical Policy Committee review
12/11/2019	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/03/2020	Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

12/09/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

12/02/2021 Medical Policy Committee review

12/08/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

02/15/2022 Coding update

12/01/2022 Medical Policy Committee review

12/14/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

12/07/2023 Medical Policy Committee review

12/13/2023 Medical Policy Implementation Committee approval. Added a “When Services Are Not Covered” section for repeat germline testing.

Next Scheduled Review Date: 12/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)®, copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0234U, 81302, 81303, 81304, 81404, 81406
HCPCS	No codes
ICD-10 Diagnosis	All related Diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Genetic Testing for Rett Syndrome

Policy # 00369

Original Effective Date: 11/20/2013

Current Effective Date: 01/08/2024

- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.